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ABSTRACT
Background The impact of COVID-19 on pregnant 
inflammatory bowel disease (IBD) patients is currently 
unknown. Reconfiguration of services during the pandemic 
may negatively affect medical and obstetric care. We 
aimed to examine the impacts on IBD antenatal care and 
pregnancy outcomes.
Methods Retrospective data were recorded in 
consecutive patients attending for IBD antenatal care 
including outpatient appointments, infusion unit visits and 
advice line encounters.
Results We included 244 pregnant women with 
IBD, of which 75 (30.7%) were on biologics in whom 
the treatment was stopped in 29.3% at a median 28 
weeks gestation. In addition, 9% of patients were on 
corticosteroids and 21.5% continued on thiopurines. 
The care provided during 460 patient encounters was 
not affected by the pandemic in 94.1% but 68.2% were 
performed via telephone (compared with 3% prepandemic 
practice; p<0.0001). One- hundred- ten women delivered 
111 alive babies (mean 38.2 weeks gestation, mean 
birth weight 3324 g) with 12 (11.0%) giving birth before 
week 37. Birth occurred by vaginal delivery in 72 (56.4%) 
and by caesarean section in 48 (43.6%) cases. Thirty- 
three were elective (12 for IBD indications) and 15 
emergency caesarean sections. Breast feeding rates were 
low (38.6%). Among 244 pregnant women with IBD, 1 
suspected COVID-19 infection was recorded.
Conclusion IBD antenatal care adjustments during the 
COVID-19 pandemic have not negatively affected patient 
care. Despite high levels of immunosuppression, only a 
single COVID-19 infection occurred. Adverse pregnancy 
outcomes were infrequent.
INTRODUCTION
The initial wave of the Sars- cov-2 pandemic 
led to vast disruption of patients’ lives and 
was also associated with significant morbidity 
and mortality.1 Furthermore, it led to many 
vulnerable patients shielding and avoiding 
hospitalisations in order to protect them-
selves from what they perceived as a risk. 
As all women are at an increased risk of 
viral respiratory infections during preg-
nancy,2 there was concern that pregnancy 
may be an independent risk factor for both 
acquiring COVID-19 and higher severity of 
Summary box
What is already known about this subject?
 ► The COVID-19 pandemic has impacted the ability to 
provide care for patients with inflammatory bowel 
disease (IBD).
 ► Pregnant women with active IBD are at an increased 
risk of adverse pregnancy outcomes.
 ► Changes to IBD antenatal care could adversely im-
pact maternal and fetal outcomes.
What are the new findings?
 ► IBD antenatal care was mainly provided remotely 
during the COVID-19 pandemic.
 ► The medical care provided was not affected by the 
pandemic in 94%.
 ► Continuation rates for biologics in the third trimester 
were higher than expected.
 ► Levels of adverse maternal and fetal outcomes were 
low.
How might it impact on clinical practice in the 
foreseeable future?
 ► Clinicians looking after pregnant women with IBD 
should aim to maintain routine standards of care 
during the pandemic.
 ► Women with IBD should be reassured that we have 
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the infection. In the UK, pregnant women in their third 
trimester were considered moderate risk and hence were 
advised to stay at home as much as possible and adhere to 
strict social distancing.3
Pregnant women do not appear to be at a higher risk 
of contracting COVID-19.4 The PregCov-19 study of 
11 000 patients found common symptoms of fever, cough 
with less frequent symptoms of dyspnoea, myalgia, loss 
of sense of taste and diarrhoea.5 The third trimester of 
pregnancy was associated with increased risk of hospi-
talisation,6 and women were five times more likely to be 
admitted to intensive care in their second half of preg-
nancy with COVID-19.7
Compared with women who were not pregnant, preg-
nant or recently pregnant women who acquired COVID-19 
were more likely to need admission to intensive care (OR: 
1.51, CI: 1.33 to 1.96) and require invasive ventilation (OR: 
1.88, CI: 1.36 to 2.60).5 COVID-19 infection has been asso-
ciated with adverse pregnancy outcomes including a three 
times greater risk of preterm birth,5 and a higher incidence 
of caesarean section with 50% attributed to maternal or 
fetal compromise.6 To date, there seems to be no significant 
increase in congenital abnormalities following maternal 
COVID-19 infection.8 An increased risk of stillbirth has 
been reported in a single- centre study during the pandemic 
(n=16, 9.31 per 1000 births) compared with prepandemic 
(n=4, 2.38 per 1000 births; p=0.01), but as others studies 
have not replicated this result, the findings should be inter-
preted with caution.9
Inflammatory bowel disease (IBD) is diagnosed in 50% 
of cases under the age of 35 and affects many women of 
childbearing age.10 About 25% of women will conceive 
for the first time following their diagnosis of IBD.11 
Women of childbearing age with coexisting IBD should 
be counselled on fertility, efficacy of contraceptives, medi-
cations used to control IBD, teratogenicity and delivery 
methods.12 Approximately, a third of patients in remission 
will relapse,13 with almost two- thirds with active disease at 
conception having further flare ups during pregnancy.14 15 
This is especially important as active IBD is considered 
an independent risk factor for poorer outcomes from 
COVID-19 in general and hence optimal disease control 
during pregnancy is vital for both the pregnant woman 
and the foetus.16 To date, the impact on IBD pregnancies 
during the COVID-19 pandemic remains to be established.
Service restructuring during the pandemic may also 
contribute to the impact of COVID-19 on pregnant patients 
with IBD. Patients may have experienced reductions in 
antenatal and postnatal appointments, reduced access 
to midwife led birth settings and alternative methods of 
screening for gestational diabetes and fetal growth restric-
tion. There has also been an increase in telemedicine, 
virtual appointments and reduction in face- to- face appoint-
ments during the COVID-19 pandemic.17
We therefore aimed to investigate the impact on the 
provision of IBD antenatal care and pregnancy outcome 
of women with IBD during the COVID-19 pandemic in the 
UK.
METHODS
The study captured routinely collected clinical data 
arising from IBD antenatal care. Consecutive patients 
attending for IBD antenatal care at 13 British hospitals 
(Wolverhampton, Newcastle, Leeds, Hull, Bristol Royal 
Infirmary, Liverpool, Bolton, King’s College Hospital, 
Glasgow Royal Infirmary, St Georges, Barts and the 
London, Pennine Acute Hospitals and Sheffield) from 
March to August 2020 were recruited. All sites main-
tained a prospective patient register. Patients with a preg-
nancy of any gestational age were eligible but in many 
centres, joint obstetric IBD clinics only review patients 
after a 12- week scan demonstrating a viable pregnancy.
IBD clinicians collected data pro- and retrospectively 
on patients’ demographics (age, ethnicity), disease 
phenotype, surgical history and treatment characteristics. 
In addition, the type of patient encounter (face- to- face 
IBD clinic, telephone IBD clinic, combined antenatal 
clinic face to face, combined antenatal clinic telephone, 
IBD advice- line encounter of patients contacting their 
IBD service by phone or email), change to appointment 
type due to the pandemic and tests requested for IBD 
were recorded. Clinicians recorded whether their prac-
tice diverged from their usual care due to effects from 
the pandemic (choice of medical treatments, diagnos-
tics and follow- up). We recorded clinicians’ decisions on 
whether they would opted for a different appointment 
type or clinical management had it not been during the 
pandemic. We did however not use a historic prepan-
demic control group of cases and appointments. Disease 
activity was measured by Physicians Global Assessment 
(PGA) and the worst disease activity during pregnancy 
was used for all analyses. For those women who gave birth 
during the study period, we recorded gestational age at 
birth, delivery method, infant’s weight, sex and feeding 
status as well as maternal complications and congenital 
abnormalities.
The study was conducted as a pragmatic clinical audit 
and hence no sample size calculations were performed. 
Data were predominantly presented in descriptive 
manner. Analysis was performed using SPSS (V.22). χ2 
was used to establish difference between categorical vari-
ables. Significance was considered when p value was<0.05.
This project was considered a clinical audit service 




A total of 244 women (mean age 31.3 years; 93.4% cauca-
sian) were included (table 1). Of these, 110 (45.1%) 
had a diagnosis of Crohn’s disease (CD), 124 (50.8%) 
ulcerative colitis (UC) and 10 (4.1%) were classed as 
IBD- unclassified (IBD- U). Further details on phenotype, 
parity and surgical treatment history are displayed in 
table 1. Data on worst disease activity during pregnancy as 
assessed by PGA were available for 232 women. Of these, 
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139 (59.9%) were in remission, 45 (19.4%) had mild, 41 
(17.7%) moderate and 7 (3.0%) severe disease activity. 
Medical treatment given during pregnancy included 
mesalazine in 96 cases (39.7%), thiopurines (not with-
drawn) in 52 cases (21.5%) and biologics in 75 cases 
(30.7%). Biologic treatment was stopped in 22 (29.3%) 
cases at a median gestational age of 28 weeks. Steroids 
were given in 22 cases (9.0%).
Encounters
In total, 460 patient encounters occurred in the study 
cohort. Of these, 68.2% occurred as telephone encoun-
ters, while only 3% of encounters would have been 
conducted this way in prepandemic practice (table 2; 
p<0.0001). The number of IBD advice- line encounters 
was not different from prepandemic practice. Tests to 
assess IBD were requested in 107 encounters (23.3%) 
including 61 calprotectin, 11 bloods, 17 calprotectin 
and bloods, 8 imaging studies (5 ultrasound scans of 
the small bowel, 1 MRI small bowel, 2 MRI pelvis) and 
4 endoscopies (1 gastroscopy, 3 sigmoidoscopies). Clini-
cians were asked at each encounter whether they would 
have provided different care outside the pandemic. In 
433 encounters (94.1%), no differences in practice were 
reported. Divergent care occurred infrequently and 
included (multiple reasons per encounter possible): 
12 cases tests not ordered (remote consult—blood tests 
not possible/calprotectin not currently offered), 4 cases 
where beclomethasone instead of prednisolone was used, 
1 case of azathioprine not being started, 1 case of endos-
copy not being available, 2 cases of patients stopping 
biologics prematurely against medical advice, 5 cases 
that would have been followed up more frequently and 3 
cases that would have been examined physically if it was 
not for a remote consultation.
Pregnancy outcomes
Miscarriages occurred in nine cases (3.7% of total 
cohort) between 5 and 13 weeks of gestation and two 
medical terminations of pregnancy were performed (one 
case of triplody, one accidental exposure to tofacitinib in 
an unplanned pregnancy). At time of data cut- off for the 
study 123 pregnancies were ongoing. One hundred and 
ten women delivered 111 alive babies (one twin preg-
nancy) and no stillbirth occurred. Birth occurred at a 
mean gestational age of 38.2 weeks (median 39 weeks) 
with 12 (11.0%) births before 37 weeks of gestation. Birth 
by vaginal delivery was achieved in 62 women (56.4%; 47 
normal vaginal deliveries, 15 assisted vaginal deliveries). 
There were no differences in the rates of vaginal delivery 
between CD and UC/IBD- U (53% vs 59%; p=0.44). Of 
48 caesarean sections (43.6%), 33 were planned elective 
sections, while 15 were emergency caesarean sections. Of 
the 33 elective sections, 12 (36.4%) were undertaken for 
an IBD indication. The sex of the infant was known in 96 
cases (50 female, 46 males) and mean birth weight was 
3324 g (available for 83 infants). A low birth weight below 
2500 g occurred in five cases (6.0%) only. We recorded 







  Caucasian 197 93.40
  Mixed 1 0.50
  Asian 1 0.50
  Black 6 2.80
  Other 6 2.80
  Not stated 33
Parity
  P0 63 36.00
  P1 66 37.80
  P2 23 13.10
  P3 23 13.10
  Not stated 69
Smoking status
  Never smoker 164 81.20
  Previous smoker 32 15.80
  Current smoker 6 3.00
  Not stated 42
Diagnosis
  CD 110 45.10
  UC 124 50.80
  IBD- U 10 4.10
Phenotype UC
  UC E1 41 33.30
  UC E2 48 39.00
  UC E3 34 27.70
  Not stated 1
Phenotype CD
  A1 17 16.50
  A2 85 82.50
  A3 1 1.00
  Not stated 7
  L1 35 33.70
  L2 25 24.00
  L3 44 42.30
  L4 1 1.00
  Not stated 6
  B1 71 71.00
  B2 9 9.00
  B3 20 20.00
  Not stated 10
Perianal disease
  Current 9 8.20
  Previous 19 17.30
Previous resection surgery (all IBD 
patients)
54 22.10
Where numbers do not add up to 244 some data were not supplied.
CD, Crohn’s disease; IBD, inflammatory bowel disease; IBD- U, IBD- 
unclassified; UC, ulcerative colitis.
copyright.
 on M










astroenterol: first published as 10.1136/bm





4 Selinger CP, et al. BMJ Open Gastro 2021;8:e000603. doi:10.1136/bmjgast-2021-000603
Open access 
four congenital defects (one tongue tie, one cleft lip 
and palate, one ‘boggy’ head, one hypospadias/bilateral 
talipes). Breast feeding was recorded for 34 of 88 (38.6%) 
documented cases and patients exposed to biologics 
were not less likely to breastfeed (p=1). Admissions to 
special care baby units (intermediate intensity care but 
not requiring neonatal intensive care) were required 
in 30 of 102 documented (29.4%) cases. Complications 
occurred in 27 cases (24.5%) and included 21 maternal 
labour- related problems (2 lacerations, 9 second- degree 
tears, 3 third degree tears, 1 post- partum haemorrhage, 
1 gestational diabetes, 1 vaginal wall prolapse, 1 wound 
infection, 1 failed instrumental delivery). Three maternal 
IBD- related problems were recorded (one intestinal 
obstruction, one small bowel perforation, one postde-
livery readmission with pain and normal cross sectional 
imaging). Four fetal problems included growth retarda-
tion, two cases of fetal distress and a case of meconium 
aspiration syndrome.
COVID-19 infections
No documented COVID-19 infections (PCR positive) 
were recorded but one woman reported typical symp-
toms of COVID-19 including dyspnoea, dry cough and 
anosmia. As she did not require hospital admission, 
COVID-19 testing was not available to her at the time. 
The patient recovered without sequalae for herself or the 
infant.
DISCUSSION
The COVID-19 pandemic poses a threat for patients at 
a higher risk of adverse outcomes,1 but during the early 
phase of the pandemic, it was difficult to ascertain which 
patients fell into the high risk category. Patients with 
active IBD, relevant comorbidities and those on immu-
nosuppressive therapy are considered higher risk.18 It 
remains unclear whether pregnancy posed an additional 
risk factor.5 In addition to the risk to the expectant mother 
inadequate control of inflammation from IBD is associ-
ated with adverse fetal outcomes.10 Any changes to IBD 
antenatal care therefore posed a potential additional risk 
by patients potentially being lost to follow- up, avoiding 
necessary medication, inability to undergo some IBD 
investigations and less frequent follow- up. In light of this, 
it is reassuring that we found a very low COVID-19 infec-
tion rate and a low rate of adverse pregnancy outcomes 
in a large multi- centre cohort of pregnant women with 
IBD in the UK.
We observed significant changes in the way that IBD 
antenatal care was delivered as the majority of appoint-
ments were held by telephone rather than face to face. 
Similar changes have occurred in general IBD clinics.17 
Telephone appointments are effective in a pandemic but 
clinician and patient may not wish to continue with this 
approach after the pandemic if telephone antenatal IBD 
care were to remain the main method of consultation. 
The addition of an option to conduct remote consulta-
tions after the pandemic should however be considered 
for those appointments where a scan or examination are 
not required. The medical care delivered was only altered 
in 6% of appointments. The IBD and obstetric services 
have managed to continue the delivery of safe and effec-
tive care during the pandemic. We observed only one 
suspected case of COVID-19, which may be attributed to 
remote care reducing exposure risk where appropriate, 
patients engaging strictly with social distancing measures 
and clinicians aiming to reduce patients COVID-19 risks 
(avoidance of systemic corticosteroids for example). In 
our study, it appears that pregnant women with IBD were 
not at excessive risk of contracting COVID-19. This may 
reflect patients’ behaviour who may have opted to avoid 
social contacts. However, our sample size is insufficient to 
provide definite evidence on the risk of COVID-19 infec-
tion in pregnant women with IBD.
The outcomes of the 110 deliveries are reassuring, with 
a low rate of babies small for gestational age or deliv-
ered prematurely. We observed a caesarean section rate 
of 46%, which was predominantly due to elective inter-
ventions. This is somewhat in excess of the literature 
reporting outcomes outside the pandemic as we would 
have expected a 1.5 times increase over the rates seen 
usually in the UK general population (between 20% and 
30% depending on centre).19 Only about a third of these 
were for IBD indications and it is possible that patient 
Table 2 Patient encounters during the pandemic and normally planned type of patient encounter prepandemic
Encounters % Normally planned encounters %
Face to face IBD clinic 24 5.2 140 30.4
Telephone IBD clinic 148 32.2 11 2.4
Combined antenatal clinic face to face 71 15.4 174 37.8
Combined antenatal clinic telephone 102 22.2 3 0.6
IBD advice line encounter 105 22.8 101 21.9
Other encounter (infusion unit, day ward) 8 1.7 0 0
Not documented 2 0.4 31 6.7
χ2 equals 5144.742. The two- tailed P value is less than 0.0001. Normally planned encounters reflect the type of encounter that would have 
occurred outside the COVID-19 pandemic.
IBD, inflammatory bowel disease.
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wishes and obstetric thresholds for caesarean sections 
could have changed during the pandemic. We also 
observed a lower than expected breast feeding rate of 
just 39%. The reason for this remains obscure but women 
with IBD may have wanted to reduce any potential trans-
mission of immunosuppressive therapies to their infant 
during the pandemic. Interestingly, the discontinuation 
of biologics during pregnancy was low at 29%. In the 
UK, IBD services usually observe the European Crohn’s 
and Colitis guidelines and base decisions on stopping or 
continuing biologics on individual risk assessments in 
contrast to the approach with uninterrupted biological 
therapy through pregnancy in American guidelines.10 20 21 
Clinicians in the UK will mostly stop biologics prior to 
the third trimester unless the patient has active IBD or a 
history of difficult to control IBD. As such we assume that 
a shift towards more continuation of biologics occurred 
during the pandemic; alternatively, this could be a 
general change to a less conservative approach among 
UK gastroenterologists running specialist antenatal IBD 
clinics.
The strength of our study lies in a large multicentre 
cohort representing experiences from a diverse set of 
UK hospitals. This has allowed us to report on a large 
number of pregnancy outcomes in a relatively short 
period of time. There are, however, a number of limita-
tions to our work. The study was performed in 12 UK 
centres with an interest in IBD antenatal care and outside 
these centres and indeed outside the UK, approaches to 
care may be different. We have previously shown that 
there are significant variations in UK IBD antenatal care 
and it is likely that the care in these 12 research active 
centres may differ from other non- specialist settings. The 
nature of predominantly retrospective data collection 
has led to some missing data, which may introduce bias. 
We have also chosen to report the findings now to inform 
clinicians and patients rather than to wait for all women 
to complete their pregnancy.
In conclusion, we have shown that despite changes to 
the delivery of IBD antenatal services, safe care was deliv-
ered with low COVID-19 infection rates and low rates of 
adverse pregnancy outcomes.
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